linjc16/ctgov huggingface dataset:
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Study Overview
=================
Brief Summary
-----------------
A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Official Title
-----------------
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Conditions
-----------------
COVID-19 Pneumonia

Intervention / Treatment
-----------------
* Drug: The group of patients who received Lianhua Qingwen orally
* Other: The group of patients who did not receive Lianhua Qingwen orally


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission. The clinical symptoms were classified as mild or ordinary. They have been vaccinated against the COVID-19. Exclusion Criteria: Patients receiving antiviral or antibiotic drugs Severe and critical patients with COVID-19. Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study. Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases. Allergic reaction to Lianhua Qingwen granules. Excluded patients treated with the same drug as Lianhua Qingwen.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Patients without Lianhua Qingwen treatment. | Other: The group of patients who did not receive Lianhua Qingwen orally<br>* The group of patients who did not receive Lianhua Qingwen orally.<br>|
| Observation Group<br>Patients with Lianhua Qingwen treatment. | Drug: The group of patients who received Lianhua Qingwen orally<br>* Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disappearance rate of symptoms | Disappearance rate of symptoms (fever, fatigue, cough) | two weeks |
Virtual Reality (VR) Regulators

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test how well a virtual reality simulation helps adults learn new skills for managing children's emotions.

Official Title
-----------------
VR Regulators: Teaching Adults to Manage Children's Big Emotions Through a Brief Virtual Reality Simulation

Conditions
-----------------
Emotion Regulation

Intervention / Treatment
-----------------
* Behavioral: Virtual Reality


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult 18 years old or higher AND Caregiver of a child ages 3-6 years old OR educator or child allied health or medical professional that regularly works with children ages 3-6 years old Exclusion Criteria: adults who do not speak English or Spanish adults with a history of significant motion sickness, active nausea, and vomiting or epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Virtual Reality Group<br>Participants in this group will receive the virtual reality simulation for up to 6 weeks. | Behavioral: Virtual Reality<br>* The virtual reality simulation includes a one time viewing of a brief video tutorial and then trying out a one time virtual reality simulation with a child avatar that takes 10-20 minutes to complete in-person.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adult Emotion Regulation as measured by the Difficulties in Emotion Regulation Scale | Score ranges from 18-90 with higher scores representing more problems with emotion regulation. | Baseline | 
| Changes in adult responses to child emotions as measured by the Adult Responses to Young Children's Strong Emotions Scale | Score ranges from 7-35 with higher scores representing a higher frequency of reported or planned use of adaptive emotion regulation responses to children | Baseline, up to 10 minutes post-intervention, 1 month post-intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction as measured by the Virtual Reality Satisfaction Survey | Score ranges from 5-25 with higher scores representing higher satisfaction with the virtual reality simulation | up to 10 minutes post-intervention |
Prognostic Interest of Vasorin in Septic Shock

Study Overview
=================
Brief Summary
-----------------
In septic shock, the intensity and duration of low blood pressure can lead to a critical reduction in renal tissue perfusion and lead to the onset of more or less severe Acute Kidney Injury (AKI). Vasorin (Vasn) is a protein strongly expressed in large vessels and kidneys, whose functions are still poorly known. Previous experimental studies show that Vasn is associated with decreased Angiotensin II concentrations, a vessel contractility defect and early mortality. The investigators hypothesize that Vasn (the potential direct regulator of blood pressure) would be an early biomarker predicting the severity of AKI post septic shock, which may be associated with mortality from septic shock or lead to longer-term Chronic Renal Failure (CKD).

Official Title
-----------------
Prognostic Interest of Vasorin in Septic Shock

Conditions
-----------------
Sepsis, Acute Kidney Injury

Intervention / Treatment
-----------------
* Biological: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years old. Hospitalized in intensive care or medical resuscitation units. With a septic shock state defined by 2 mmol/l lactate sepsis, requiring vasopressors to maintain mean blood pressure 65 mmHg (despite adequate vascular filling). Whether or not they have developed AKI. Patient/family information and collection of non opposition Exclusion Criteria: Patients with chronic respiratory failure. Pregnant women. Patients in palliative care. Information for the patient/someone close and collection of his opposition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Blood sampling|Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between vasorin concentration at day 0 and mortality rate |  | day 0 | 
| correlation between vasorin concentration at day 3 and mortality rate |  | day 3 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vasorin, Sepsis, angiotensin II, Acute Kidney Injury
A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

Study Overview
=================
Brief Summary
-----------------
This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

Detailed Description
-----------------
We will be confirming that the patients are HIV positive and has antibodies to either HSV 1 or HSV 2 as part of the screening process. If so, we will then obtain patient baseline HIV-PCR, CD4, medial history including medications on day one. Whether the patient is on any or no herpes controlling medication. If the patient has what they feel is a flare up of HSV, they will come into clinic where the lesion will be culture and the patient's HIV-PCR and CD4 will also be obtained. Otherwise, the patient will receive phone follow ups every three months to see if there has been and change in their health or medications. The main endpoint is to see if there is a correlation between outbreaks in HIV patients and their CD4 cells and/or HIV and/or Herpes medication.

Official Title
-----------------
A 48 Week Observational Study of the Frequency of Symptomatic Herpes Virus I and II in HIV Infected Subjects

Conditions
-----------------
HIV Disease, Herpes Simplex 1, Herpes Simplex 2

Intervention / Treatment
-----------------
* Other: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be 18 years or older at the time of screening Males, Females, Transgender Male and Transgender Females HIV positive Positive antibody to HSV- 1/and or HSV-2 If Female of child baring potential, documented negative pregnancy test at the time of screening. Exclusion Criteria: Active opportunistic infection Current chemotherapy Unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Blood draw|We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiology | The frequency of HSV outbreaks in HIV positive patients. | 48 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Co Morbidity | Correlation of HSV outbreak with patient CD4 count and/or HIV-PCR | 48 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, Herpes Simplex 1, Herpes Simplex 2
Biomechanical Functional Evaluation of Plantar Pressures After Foot and Ankle Surgeries

Study Overview
=================
Brief Summary
-----------------
The described surgical techniques for the treatment of foot and ankle pathologies are numerous. In order to objectively assess the outcomes of these procedures, evaluation methods are typically used, primarily considering pain symptoms, residual functionality, the correction of any deformities achieved, and radiographic parameters. Conversely, assessments of plantar pressures, as a potential indicator of functional and biomechanical recovery, are still not widely utilized. Biomechanical functional assessments examine specific variables, including gait analysis, stabilometry, kinematics and kinetics of joint movements, and the activation and strength of particular muscle groups. These assessments can be conducted by specialized personnel using dedicated equipment such as a baropodometric platform and inertial sensors. This study aims to, for the first time in the literature, present the results related to plantar pressures from different surgical treatments of the foot and ankle

Official Title
-----------------
Biomechanical Functional Evaluation of Plantar Pressures After Foot and Ankle Surgeries

Conditions
-----------------
Plantar Pressure

Intervention / Treatment
-----------------
* Other: Plantar pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who need to undergo surgical intervention Patients of both sexes aged between 18-75 years Patients who have provided their written informed consent to participate in the study Patients who have expressed their willingness to attend the Institute for the 6-month follow-up Exclusion Criteria: Patients with severe postural instability Patients with cognitive deficits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Post-surgical foot and ankle patients<br> | Other: Plantar pressure<br>* Biomechanical functional assessments investigate specific variables: gait analysis, stabilometry, kinematics and kinetics of joint movements, activation, and strength of specific muscle groups.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale |  | At baseline (day 0) | 
| Visual Analogue Scale |  | After 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
foot, ankle, Post-operative, plantar pressure
AIMN Multicenter Study: 18 F-FDG PET-CT With or Without Contrast Medium in the Staging and Radiation of Lung Cancer?

Study Overview
=================
Brief Summary
-----------------
Accurate staging of patients with non-small cell cancer (NSCLC) is of fundamental importance both for the correct choice of treatment plan and for prognosis. Numerous studies have demonstrated the added value of co-registration of functional PET images and anatomical CT images using hybrid PET-CT tomographs and the consequent benefits on the choice of treatment in patients with NSCLC. Currently in most PET centers CT is performed with a low dose technique and is used exclusively as a transmissive source for attenuation correction and anatomical localization. The availability of new generation hybrid tomographs allows for diagnostic CT examinations (contrast CT) to be performed with a standard dose of radiation and with the use of intravenous and/or oral iodinated contrast medium (contrast medium). Little data is currently available on the added value of a PET-CT scan performed in a single session compared to PET-CT performed independently and, generally, subsequently to CT scan. The objective of the study is to evaluate the ability to correctly define the accuracy in localizing and characterizing lung lesions in patients with confirmed NSCLC, in the staging or restaging phase, through the use of: PET-CT low-dose and PET contrast CT. The effects of the two procedures on the patient's quality of life and on the costs incurred by the patient and the healthcare service will also be evaluated.

Official Title
-----------------
AIMN Multicenter Study: 18 F-FDG PET-CT With or Without Contrast Medium in the Staging and Radiation of Lung Cancer?

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: PET/CT with contrast medium in a single session.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with histologically proven NSCLC, undergoing staging or restaging; plasma creatinine normal; Exclusion Criteria: patients with lung microcytoma; pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET/CT with contrast medium in a single session.|Patients will undergo low dose PET/CT with FDG. Following the PET exam, a Standard CT with contrast medium will be acquired, using the CT tomography inserted inside the PET.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of PET and CT with contrast in a single session | In patients with confirmed NSCLC, evaluate the diagnostic accuracy of low dose PET-CT and contrast-enhanced PET CT | 1 year |
Polygraphy at Home for Neuromuscular Patients Under Non-invasive Mechanical Ventilation

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to evaluate the feasibility, the quality and the utility of a polygraphic control at home in order to appreciate the efficacy of the night time non-invasive ventilation (allowing to optimize the ventilator settings when the results are not satisfactory).

Official Title
-----------------
Initiation of Polygraphy for Neuromuscular Disease Patients Under Non-invasive Mechanical Ventilation

Conditions
-----------------
Neuromuscular Diseases

Intervention / Treatment
-----------------
* Procedure: Polygraphy diagnostic at home


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ≥ 18 years; Patient with chronic respiratory insufficiency has just been posed non-invasive ventilation (NIV) in the hospital, according to the latest international recommendations ; Affiliation to the social security scheme; Patient has signed the informed consent form to participate to the study. Exclusion Criteria: Patient refusal; Patient under guardianship; Patient under AME scheme; Patients living more than 40 km from reference center; Patient depending on mechanical ventilation (more than 6 hours daily); Rapidly or reversible evolutive neuro-myopathy (Amyotrophic lateral sclerosis, Guillain Barré syndrome, myasthenia).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Initiation a non-invasive ventilation at night<br>Neuromuscular patients with chronic respiratory failure who initiate a non-invasive ventilation at night. | Procedure: Polygraphy diagnostic at home<br>* Polygraphy diagnostic at home for patients under non-invasive mechanical ventilation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gradation of quality of recorded signals at home | Expressed in number of readable signals for which the readability will be expressed in % of record time. | at day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuromuscular Diseases, Polygraphy
Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone

Study Overview
=================
Brief Summary
-----------------
To conduct a RCT comparing SWL versus combined ODT and SWL as non-invasive methods for management of paediatrics radiolucent renal stone.

Official Title
-----------------
Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone. A Randomised Controlled Trial

Conditions
-----------------
Pediatric Kidney Disease

Intervention / Treatment
-----------------
* Device: SWL
* Combination Product: SWL and ODT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1-2.5 cm renal stone Normal Serum creatinine Radiolucent stone with Hounsfield units less than 400 Exclusion Criteria: Bleeding diatheses. Patients with a pacemaker. uncontrolled UTIs. Severe skeletal malformations. Arterial aneurysm in the vicinity of the stone. Anatomical obstruction distal to the stone.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SWL<br>Shockwave Lithotripsy (SWL) | Device: SWL<br>* Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone<br>|
| Active Comparator: SWL and ODT<br>Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) | Combination Product: SWL and ODT<br>* Shockwave Lithotripsy (SWL) and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the stone free rate measured by computed tomograghy as asymptomatic insignificant residual fragments less than 3 mm | percentage of patient who are stone free | 3 month |